Notice of Preliminary Results

RNS Number : 4095O

Avacta Group PLC

19 September 2011

 



Press release

19 September 2011

Avacta Group plc

("Avacta" or "the Group")

Notice of Preliminary Results

Avacta Group plc (AIM:AVCT), a leading provider of analytical and diagnostic technologies and services to the pharmaceutical and animal healthcare sectors, will be announcing its Preliminary Results for the year ended 31 July 2011, on Tuesday, 25 October 2011.

An analyst briefing given by Alastair Smith, Chief Executive Officer, Tim Sykes, Chief Financial Officer and Gwyn Humphreys, Non Executive Chairman, will be held at 09:30hrs on Tuesday, 25 October 2011 at Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.

-Ends-

For further information please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer	Tel:  [phone] www.avacta.com
Broker XCAP Securities plc John Grant/Karen Kelly/Parimal Kumar	Tel:  [phone] www.xcapgroup.com
Nominated Adviser Grant Thornton Corporate Finance Colin Aaronson/David Hignell/Philip Secrett	Tel:  [phone] www.grantthornton.co.uk
Media Enquiries Abchurch Communications Sarah Hollins/Adam Michael/Oliver Hibberd [e-mail]	Tel: [phone] www.abchurch-group.com

Notes to Editors:

Avacta Group plc, a world leading, UK-based healthcare equipment and instrumentation business, provides innovative, high value proprietary technologies and services to the life sciences/healthcare sector through two operating divisions:

Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a $200bn revenues market by 2013 and the fastest growing part of the pharmaceutical industry. The Group's technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Group's lead analytical instrument, Optim, is distributed through Pall Corporation in the US, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.

Avacta Animal Health provides diagnostic products and services for the $1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information, through point of care diagnostics, reagents and testing kits and laboratory based testing. Avacta's AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta's world leading allergy testing brand Sensitest®.Avacta is currently developing further assays for the AX-1 system to diagnose other diseases in companion animals. Longer term this technology will be transferred into the human clinical diagnostics market.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

END

 

 

NORLQLFFFKFEBBK